DIAGNOSTICOS DA AMÉRICA S.A. Financials Diagnosticos da América S.A.
Equities
DASA3
BRDASAACNOR1
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.65 BRL | +10.27% |
|
+14.78% | -62.06% |
| Jun. 14 | Brazil's Dasa, Amil to combine hospital businesses | RE |
| Jun. 10 | Brazil's Dasa, Amil in advanced talks to combine hospital businesses | RE |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 34,851 | 18,485 | 7,686 | 7,186 | 2,727 | - | - |
| Enterprise Value (EV) 1 | 34,851 | 26,409 | 7,686 | 16,167 | 13,002 | 13,149 | 13,944 |
| P/E ratio | - | -90.8 x | -19.8 x | -6.16 x | 68.4 x | 6.99 x | 11.4 x |
| Yield | - | 0.89% | - | - | 0.11% | 1.82% | 2.19% |
| Capitalization / Revenue | 4.95 x | 1.77 x | 0.59 x | 0.46 x | 0.18 x | 0.17 x | 0.16 x |
| EV / Revenue | 4.95 x | 2.53 x | 0.59 x | 1.04 x | 0.84 x | 0.8 x | 0.81 x |
| EV / EBITDA | - | 20.6 x | 3.54 x | 6.91 x | 4.93 x | 4.31 x | 4.17 x |
| EV / FCF | - | -7.23 x | - | -9.11 x | 29.1 x | 13.9 x | 11.4 x |
| FCF Yield | - | -13.8% | - | -11% | 3.44% | 7.22% | 8.78% |
| Price to Book | - | 2.51 x | - | 0.99 x | 0.39 x | 0.38 x | - |
| Nbr of stocks (in thousands) | 480,705 | 547,872 | 559,827 | 746,960 | 747,191 | - | - |
| Reference price 2 | 72.50 | 33.74 | 13.73 | 9.620 | 3.650 | 3.650 | 3.650 |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 7,039 | 10,419 | 13,129 | 15,557 | 15,392 | 16,463 | 17,282 |
| EBITDA 1 | - | 1,282 | 2,168 | 2,339 | 2,638 | 3,050 | 3,340 |
| EBIT 1 | - | 351.7 | 1,102 | 913.3 | 1,407 | 1,798 | 1,905 |
| Operating Margin | - | 3.38% | 8.39% | 5.87% | 9.14% | 10.92% | 11.02% |
| Earnings before Tax (EBT) 1 | - | -374.2 | -578.8 | -996 | -6.077 | 428.6 | 363.4 |
| Net income 1 | -150.8 | -226.6 | -386.9 | -1,130 | -80.55 | 348.4 | 446.1 |
| Net margin | -2.14% | -2.17% | -2.95% | -7.26% | -0.52% | 2.12% | 2.58% |
| EPS 2 | - | -0.3715 | -0.6932 | -1.561 | 0.0533 | 0.5225 | 0.3200 |
| Free Cash Flow 1 | - | -3,654 | - | -1,775 | 447 | 949 | 1,224 |
| FCF margin | - | -35.07% | - | -11.41% | 2.9% | 5.76% | 7.08% |
| FCF Conversion (EBITDA) | - | - | - | - | 16.94% | 31.12% | 36.64% |
| FCF Conversion (Net income) | - | - | - | - | - | 272.41% | 274.36% |
| Dividend per Share 2 | - | 0.3012 | - | - | 0.004000 | 0.0666 | 0.0800 |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,673 | 3,136 | 3,288 | 3,425 | 3,279 | 3,534 | 3,631 | 3,769 | 3,777 | 3,728 | 3,786 | 3,900 | 3,708 | 3,930 |
| EBITDA | 222.9 | 560.5 | 512.3 | 607.3 | 457.6 | 615.7 | 526.1 | 660.8 | 438 | 638.7 | - | - | - | - |
| EBIT 1 | -39.21 | 288.4 | 227.3 | 307.9 | 208 | 306 | 215.4 | 331 | 60.98 | 303.2 | 297.4 | 397.2 | 214.9 | 349.2 |
| Operating Margin | -1.47% | 9.2% | 6.91% | 8.99% | 6.34% | 8.66% | 5.93% | 8.78% | 1.61% | 8.13% | 7.85% | 10.19% | 5.8% | 8.89% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | -167.1 | 37.11 | -120.1 | -89.36 | -214.6 | -166 | -282.1 | -180.5 | -495 | -176 | - | - | - | - |
| Net margin | -6.25% | 1.18% | -3.65% | -2.61% | -6.54% | -4.7% | -7.77% | -4.79% | -13.11% | -4.72% | - | - | - | - |
| EPS 2 | -0.2630 | 0.0636 | -0.2145 | -0.1592 | -0.3853 | -0.3019 | -0.3803 | - | - | -0.2355 | -0.1200 | 0.0200 | -0.2100 | -0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/28/23 | 5/12/23 | 8/10/23 | 11/9/23 | 3/28/24 | 5/15/24 | - | - | - | - |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 7,924 | - | 8,981 | 10,275 | 10,421 | 11,217 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 6.183 x | - | 3.84 x | 3.895 x | 3.417 x | 3.358 x |
| Free Cash Flow 1 | - | -3,654 | - | -1,775 | 447 | 949 | 1,224 |
| ROE (net income / shareholders' equity) | - | -4.09% | - | -16.2% | 3.1% | 6.23% | 5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 13.50 | - | 9.740 | 9.420 | 9.650 | - |
| Cash Flow per Share | - | 2.320 | - | -1.290 | - | - | - |
| Capex 1 | - | 4,952 | - | 727 | 994 | 951 | 860 |
| Capex / Sales | - | 47.53% | - | 4.67% | 6.46% | 5.77% | 4.97% |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.65
BRL
Average target price
9.061
BRL
Spread / Average Target
+148.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -62.06% | 500M | |
| +19.84% | 84.94B | |
| -25.24% | 74.07B | |
| -1.34% | 26.15B | |
| +4.56% | 18.03B | |
| -9.29% | 17.38B | |
| +4.52% | 16.01B | |
| +78.16% | 13.7B | |
| +77.84% | 13.13B | |
| -26.14% | 12.74B |
- Stock Market
- Equities
- DASA3 Stock
- Financials Diagnosticos da América S.A.
